^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:ALRN-6924 (MDM2 inhibitor, MDMX inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

    Excerpt:
    ...wild type (WT) TP53 status defined as...
    Trial ID:
    NCT03725436
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

    Excerpt:
    We therefore sought to evaluate the combined antitumor efficacy of ALRN-6924 and paclitaxel or eribulin in ER+ breast cancer with WT TP53...ALRN-6924 was active in wild-type TP53 (WT-TP53) cancer cell lines, but not mutant TP53. On ER+ breast cancer cell lines, it was synergistic in vitro and had enhanced in vivo antitumor activity with both paclitaxel and eribulin….The significant synergy observed with ALRN-6924 in combination with chemotherapeutic agents supports further evaluation in patients with hormone receptor-positive breast cancer.
    Secondary therapy:
    E7386; bisphosphonate bound paclitaxel
    DOI:
    10.1186/s13058-021-01406-x